about
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinA general method to correct PET data for tissue metabolites using a dual-scan approach.Image-guided cancer therapy using PET/CT.Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncologyMulticenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.Bevacizumab plus ipilimumab in patients with metastatic melanoma.CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical toolNew Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapyMetabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanomaA phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibodyPhase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission TomogrFDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.Considerations for the use of imaging tools for phase II treatment trials in oncology.Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.The influential role of BCL2 family members in synovial sarcomagenesis.Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.Correlation of Glioma Proliferation and Hypoxia by Luciferase, Magnetic Resonance, and Positron Emission Tomography Imaging.Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cEvaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning.Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trialAssessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PETOn-line measurement of exhaled [11C]CO2 during PETModulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug actionProtective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
P50
Q27851724-229BF483-F208-4F46-AA7A-BAF115A9086CQ27852360-E12C8C5A-35E7-48B9-BFDB-BEFBC973F8F0Q30591271-A9F618A0-7224-4938-809C-EBF50CF15D6AQ30961536-959A7687-FF41-4619-A18F-1363E4BF3F9DQ33835371-D4FF5B06-D903-4920-A3AF-489B0489B86EQ34607838-CBFF9AF1-2338-40DD-BBF4-E816A68EDC1BQ35012765-4567EE3C-597D-4A9C-8365-3E89856DBBAAQ35086187-FCEC7C62-103B-47D4-BFD1-B275E5CA5F59Q35088122-249D066F-CDE7-463C-990A-3A3B0C9753F3Q35093281-FF37B5A2-2FBE-46A0-9F4A-F1FD57430A02Q35567261-62DB63FB-75C3-456F-A090-699C7DD33B4CQ35785799-BDCFAF7B-B82B-48DE-84CF-D7BDA6D4FD04Q35947019-E8BD2B36-8C91-4DED-85E6-67758218F1DEQ36023626-F9DB7106-A4BF-4DFF-9D63-55CD2EF9647DQ36104734-EB0C9B79-9F44-4E6E-B7BE-199C0CB4261AQ36495076-505933A2-C242-495F-9D9D-8ABF18298D15Q36793267-CD090EC4-26C6-449F-92EB-479F66626CD9Q37411854-681827A8-079C-4DB9-8DB5-5D9EB0455909Q37702328-BF9A5232-CA3F-4B6D-AA3F-5AD5E4DE6E51Q39637210-D61C9C75-CADD-4DC7-83E7-4408175981A2Q40066050-AE8B47F7-1522-4408-A8DB-5F5C0E9A1613Q44045389-1CB5ED21-B5A1-4A49-9781-04BFB9181CABQ44478859-D32B1606-4267-436E-8816-E343269E3574Q45999985-0992652F-E554-44B8-A1B9-2B96EE516CF0Q47866324-DA198488-19E2-45C3-A37C-97F7BAEC6CCCQ48541561-86A3FA0E-FE08-47FF-A899-D80B690B9C2FQ53080360-34E5DD58-3AC9-43EC-8687-AAE2328D6FDFQ53179347-3CD45E10-1D18-409D-8CC8-1BF87373F894Q53240194-00015DE7-AA89-4B7C-9F67-64304D7DDD76Q57128970-D9E9AEE6-736E-446B-8E2F-53994B653708Q73192468-854C35CA-3226-452D-8AA9-8C1745440E37Q73684313-D160051E-35F2-4FF9-A6C8-3D668C177077Q74023445-5412992D-6E0E-4C54-A925-1A3E0D5C22CEQ92129115-67209999-F753-4B0E-B361-A0C51CF7CE71
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jeffrey Yap
@ast
Jeffrey Yap
@en
Jeffrey Yap
@es
Jeffrey Yap
@nl
Jeffrey Yap
@sl
type
label
Jeffrey Yap
@ast
Jeffrey Yap
@en
Jeffrey Yap
@es
Jeffrey Yap
@nl
Jeffrey Yap
@sl
prefLabel
Jeffrey Yap
@ast
Jeffrey Yap
@en
Jeffrey Yap
@es
Jeffrey Yap
@nl
Jeffrey Yap
@sl
P106
P1153
7007107489
P21
P31
P496
0000-0001-5306-2860